Lantern Pharma (LTRN) to Release Earnings on Wednesday

Lantern Pharma (NASDAQ:LTRN) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Lantern Pharma to post earnings of ($0.38) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06.

Lantern Pharma Trading Up 5.4%

Shares of LTRN stock opened at $2.75 on Wednesday. Lantern Pharma has a twelve month low of $1.11 and a twelve month high of $5.74. The company’s 50-day moving average price is $3.45 and its 200-day moving average price is $2.89. The stock has a market cap of $35.09 million, a price-to-earnings ratio of -1.90 and a beta of 2.34.

Wall Street Analyst Weigh In

A number of equities analysts have commented on LTRN shares. Wall Street Zen raised shares of Lantern Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings raised shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Insider Activity

In related news, Director D Jeffrey Keyser purchased 48,544 shares of Lantern Pharma stock in a transaction dated Tuesday, May 12th. The shares were acquired at an average cost of $2.06 per share, with a total value of $100,000.64. Following the purchase, the director owned 94,303 shares of the company’s stock, valued at approximately $194,264.18. The trade was a 106.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lee Troy Schalop acquired 48,544 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was bought at an average price of $2.06 per share, for a total transaction of $100,000.64. Following the completion of the acquisition, the director owned 48,544 shares in the company, valued at approximately $100,000.64. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Lantern Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LTRN. Geode Capital Management LLC lifted its stake in Lantern Pharma by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock worth $293,000 after purchasing an additional 4,661 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Lantern Pharma by 10.3% in the 4th quarter. Renaissance Technologies LLC now owns 110,400 shares of the company’s stock valued at $335,000 after buying an additional 10,300 shares during the period. Cetera Investment Advisers acquired a new position in Lantern Pharma during the 4th quarter worth about $37,000. XTX Topco Ltd acquired a new position in Lantern Pharma during the 2nd quarter worth about $40,000. Finally, CIBC Private Wealth Group LLC purchased a new position in Lantern Pharma during the 4th quarter valued at about $47,000. Hedge funds and other institutional investors own 28.62% of the company’s stock.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.